Select a cancer type to view all clinical trials for that cancer, or view all currently open clinical trials below.
If you don’t see the cancer type you’re looking for, please contact us here. We may still have relevant trials or be able to assist with your search.
All Current Clinical Trials
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| PSMA-007-001 | Castrate-Resistant Prostate Cancer | A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Immunotherapy | PSMA targeting BiTE. | Open - Recruiting | Janux Therapeutics | NCT05519449 | Enquire Now |
| GRWD5769-ST-01 | Multi-Cancers | A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination With Anticancer Treatments in Patients With Solid Malignancies | Immunotherapy | Novel EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1) | Open - Recruiting | Grey Wolf Therapeutics Pty Ltd | NCT06923761 | Enquire Now |
| AWT020-001 | Multi-Cancers | A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer | Immunotherapy | Anti-PD1 IL-2 BiTE. | Open - Recruiting | Anwita Biosciences | NCT06092580 | Enquire Now |
| CP-AU-007-01 | Multi-Cancers | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Immunotherapy | IL-2 and Inhibits IL-2Rα Binding in combo. | Open - Recruiting | Aulos Bioscience, Inc. | NCT05267626 | Enquire Now |
| HMBD-001-103 | Multi-Cancers | A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers | Targeted | Humanized IgG1 anti-HER3 monoclonal antibody + Combo treatment for squamous HER3 Mutation. | Open - Recruiting | Hummingbird Bioscience | NCT05910827 | Enquire Now |
| PTT-4256-01 | Multi-Cancers | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| ADCE-T02-01 | Multi-Cancers | First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting a tissue factor. | Open - Recruiting | Adcendo ApS | NCT06597721 | Enquire Now |
| CP-IVX001 | Multi-Cancers | A Phase 1 Open-label, Non-randomized, Multi-cohort Clinical Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Injectable Lesions | Ovarian, Gastric and CRC only. Must have Injectable lesions. Intratumoral injection. Live EchoVirus, No GMO component. | Open - Recruiting | ImmVirx PtyLtd | NCT05427487 | Enquire Now |
| BI - 1456-0001 | Multi-Cancers | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | Immunotherapy | Genetically Modified Virus | Open - Recruiting | Boehringer Ingelheim | NCT05155332 | Enquire Now |
| DM002001 | Multi-Cancers | A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting MUC1 and HER3 | Open - Recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | NCT06751329 | Enquire Now |
| HRS-5041-103 | Prostate Cancer | A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | Targeted | AR-PROTAC molecule - AR degrader | Open - Recruiting | Atridia Pty Ltd | NCT06830850 | Enquire Now |
| NXT-9216-101 | Multi-Cancers | A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair | Targeted | Small molecule inhibitor of WRN helicase activity - MSI-H/dMMR tumours | Open - Recruiting | Nimbus Wadjet, Inc. | NCT06898450 | Enquire Now |
| VRN110755 | Non-Small Cell Lung Cancer (NSCLC) | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | Targeted | Small molecule EGFR inhibitor for EGFR-mutated NSCLC | Open - Recruiting | Voronoi Therapeutics | TBA | Enquire Now |
| GIANTS-1 | Cancer Survivors | A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors (GIANTS-1) | Immunotherapy | Bispecific immunocytokine composed of CD80 fused with a mutated interleukin (IL)-2. In combo with probiotic. | Open - Recruiting | GI Innovation, Inc. | NCT07363057 | Enquire Now |
| SP-03-B101 | Multi-Cancers | A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Combination with Exemestane in Patients with Advanced mTOR-sensitive solid tumors (HR+/HER2- Br Ca, RCC, NETs, TSC, HCC) | Targeted | Intravenous Everolimus. HR+ HER2- breast, HCC, RCC, NETs TSC- associated tumours | Open - Recruiting | Sapu Bioscience | ACTRN12625001083482 | Enquire Now |
| ADCE-B05-001 | Multi-Cancers | A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients with Advanced Solid Tumors | Immunotherapy | ADC anti-GPC1 IgG1 with a Topo-I inhibitor and P1021 | Open - Recruiting | Adcendo ApS | NCT07362888 | Enquire Now |
| HDM2017-101 | Multi-Cancers | A Phase 1 Study of HDM2017 in Advanced Solid Tumors | Targeted | ADC targeting CDH17 conjugated to CPT-derivative payloads | Open - Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07274085 | Enquire Now |